Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
about
Sulfasalazine-induced immune thrombocytopeniaSulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis.A review of gastrointestinal manifestations of systemic lupus erythematosus.Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden.Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group.Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazineArylamine N-acetyltransferases and drug response.Therapy of systemic lupus erythematosus: a look into the futureDrug-induced glomerular disease: immune-mediated injury.Toxic Epidermal Necrolysis-Like Lesions and Systemic Lupus Erythematosus Possibly Triggered by Sulfasalazine.N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel diseasePharmacogenomics in the treatment of inflammatory bowel disease.Inflammatory bowel disease and lupus: a systematic review of the literature.Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus.Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers.Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis?Development of lupus‐related side‐effects in patients with early RA during sulphasalazine treatment—the role of IL‐10 and HLA
P2860
Q24647121-44A35C97-5E90-4F5D-AFDF-0CD06649FB67Q33436278-E11662F2-CCB6-4F9C-9321-1A17D9CD2D67Q33759553-D1EA0680-44C7-4871-8363-6FAB0DFD867FQ34031291-149CC1A4-DA30-4503-A77C-C0A33C51D5ECQ34339975-22623940-1A27-4B0D-A2BC-AF19E9BCB252Q34587103-D47E388B-4996-4920-BF51-68FB3876532EQ34673370-30CC8398-6D50-455D-9D28-5E028A287298Q34731092-8B76A987-7F55-4300-9E3D-A87391F03EB4Q35816996-7ADC53FD-A90E-4C93-94B8-1C78CD38BBD3Q37124665-2A785932-4CA9-4D13-AE0E-8A058764A4EAQ37133431-D1A0B01F-5BFC-42AE-9D32-C49D776415C7Q37710516-B83D18F4-7968-494D-BD63-076046FB67C3Q38002687-A2F4F942-3DCF-4572-887E-202D7C3D15D8Q40099981-AB03AFCF-FE23-4E70-9BE8-610299C12986Q46496343-7E8529C5-B5AD-4808-8F05-10DD87F68EF8Q46812622-908B20C3-3261-4C45-B1A4-86F3FEA18D87Q57350977-A06B071E-1701-4768-ABA6-32ADB214583F
P2860
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
@en
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
@nl
type
label
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
@en
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
@nl
prefLabel
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
@en
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
@nl
P2093
P356
P1476
Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
@en
P2093
Gunnarsson I
Lindblad S
Pettersson E
Ringertz B
P304
P356
10.1093/RHEUMATOLOGY/36.10.1089
P577
1997-10-01T00:00:00Z